Skip to main content
. 2022 Oct 15;13(10):877–887. doi: 10.4239/wjd.v13.i10.877

Figure 3.

Figure 3

Assessment of the safety of human umbilical cord blood-mesenchymal stem cell treatment. A-C: Leukocytes, hepatic and renal function; D-F: Antigen associated with tumor. aP < 0.05.